ACONHealthcare · Health Information ServicesThe 1 Wall Street analysts covering Aclarion, Inc. hold a median 12-month price target of $7.63 — +239.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 12 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Aclarion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +239.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 May 2026 | Ascendiant Capital | Maintains | Buy | $7.00 → $7.50 |
| 25 Mar 2026 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 19 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 13 Dec 2024 | Maxim Group | Downgrade | Hold | — |
| 27 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 26 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 29 July 2024 | Ascendiant Capital | Initiates | Buy | — |
| 6 July 2022 | Maxim Group | Initiates | Buy | $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACON appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Aclarion, Inc. returned −73.9% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 4% of US stocks
Cheaper than 87% of US stocks
Cheaper than 58% of US stocks
Higher than 78% of US stocks
Higher than 65% of US stocks
Higher than 38% of US stocks
Higher than 2% of US stocks
Higher than 68% of US stocks
Higher than 19% of US stocks
Higher than 11% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aclarion, Inc. has a market value of $6.7M and an enterprise value of −$9.5M.
Revenue in the twelve months to 30 June 2026: $84K. The latest quarter grew 30.5% year on year.
Net income over the same four quarters: −$9.2M, a −10978.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$8.3M.
Aclarion, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 169.49%, paying out 0% of earnings.
Aclarion, Inc. employs 10 people — $8K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aclarion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aclarion announced it will participate in the 20th Annual LD Micro Main Event, scheduled for October 19–21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.
Why it matters — ACON watchers may note the company’s participation in this investor event.
Aclarion broadened CLARITY trial enrollment criteria, with the new criteria approved at nine of 11 active sites. The company said it expects enrollment to accelerate, will update initial readout timing by year-end based on Q4 enrollment increases, and that overall trial duration remains on track.
Why it matters — The criteria change and enrollment progress may affect the timing of updates on Aclarion’s pivotal CLARITY trial.
Aclarion announced that NYU Langone Health has joined the CLARITY trial network, which now includes eleven enrolling sites. CLARITY is a prospective, randomized clinical trial studying Nociscan's use of MR Spectroscopy and augmented intelligence to improve surgical outcomes for chronic low back pain.
Why it matters — Adding a nationally recognized academic medical center with spine surgery and clinical research expertise expands the CLARITY trial's reach, supporting progress toward validating Nociscan's clinical utility.
Aclarion announced that the University of Arizona College of Medicine - Phoenix has been added as a clinical site in its CLARITY trial, a prospective, randomized study evaluating Nociscan's ability to improve surgical outcomes for chronic low back pain. The addition brings the trial to ten actively enrolling sites.
Why it matters — A new enrolling site expands the footprint of Aclarion's key CLARITY trial, advancing progress toward validating Nociscan for identifying sources of low back pain.
Aclarion announced that the USPTO issued a Notice of Allowance for a patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," which protects the precision of MRS data capture within the target disc as part of the Nociscan workflow. The patent is designed to reduce scan time, support faster technologist onboarding, and deliver more reproducible results, extending Aclarion's IP protection to over 65 issued and pending patents worldwide.
Why it matters — ACON watchers would care because this patent allowance bolsters Aclarion's intellectual property protection around its Nociscan MRS process, potentially supporting the accuracy and broader adoption of its technology across imaging centers.
The 1 Wall Street analysts covering Aclarion, Inc. have a median 12-month price target of $7.63, with estimates ranging from $7.5 to $7.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Aclarion, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclarion, Inc. 29 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Aclarion, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +239.6% from the last close, and Ticker Nerd's factor model ranks Aclarion, Inc. 29 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aclarion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $7.75 over the next 12 months.
Aclarion, Inc. returned -73.9% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aclarion, Inc. is a healthcare technology company focused on using magnetic resonance spectroscopy and proprietary signal-processing biomarkers to support the evaluation of spine-related pain.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Aclarion to Present at the 20th Annual LD Micro Main Event". Aclarion announced it will participate in the 20th Annual LD Micro Main Event, scheduled for October 19–21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.
Aclarion, Inc. is a healthcare technology company focused on using magnetic resonance spectroscopy and proprietary signal-processing biomarkers to support the evaluation of spine-related pain. Its core product, Nociscan, is a cloud-based software platform designed to help physicians analyze intervertebral disc chemistry and identify discs associated with chronic low back pain. The company’s solutions combine imaging data, augmented intelligence, and clinical decision-support tools to improve how specialists assess pain sources and plan treatment. Aclarion serves the medical imaging and spine care markets, with current offerings centered on noninvasive diagnostics and software-based analysis for healthcare providers. Headquartered in Broomfield, Colorado, Aclarion operates at the intersection of diagnostic imaging, health information services, and precision pain assessment.
CEO Mr. Brent Ness · 10 employees · United States · https://www.aclarion.com
